hapabapa
A federal court status hearing on the Federal Trade Commission challenge to Amgen’s (NASDAQ:AMGN) planned $28 billion purchase of Horizon Therapeutics was rescheduled until next week.
The telephonic status hearing before Federal Judge John Kness has been rescheduled to 10:30 a.m. on Sept. 5 from Thursday, according to a listing on the court docket.
The rescheduling comes as the FTC on Friday paused its internal case to attempt to block the Horizon (NASDAQ:HZNP) deal as it tries to work on a settlement. The case is paused until Sept. 18 at the FTC.
The rescheduled status conference comes as the FTC is set to battle with Amgen (AMGN) in a Chicago federal courtroom on Sept. 11 as the regulator attempts to challenge the Horizon (HZNP) deal.
On Monday, CNBC reported that Amgen could come to a settlement with the FTC in the next couple weeks. The FTC staff and Amgen (AMGN) have “essentially” agreed to a settlement, where Amgen has agreed to never bundle Horizon’s Tepezza or Krystexxa drugs.
